Loading...
ROCO
4157
Market cap202mUSD
Jul 09, Last price  
9.13TWD
1D
0.33%
1Q
-18.84%
Jan 2017
-66.43%
IPO
-71.93%
Name

Taigen Biopharmaceuticals Holdings Ltd

Chart & Performance

D1W1MN
ROCO:4157 chart
P/E
143.85
P/S
25.05
EPS
0.06
Div Yield, %
—
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
61.77%
Revenues
259m
+72.24%
14,906,000225,732,00040,440,00069,875,000104,598,00078,004,000146,021,000553,208,00029,618,00020,314,00023,422,0001,294,522,00036,230,000123,134,000150,651,000259,474,000
Net income
45m
P
-2,285,618,00042,837,000-468,398,000-432,193,000-403,718,000-412,994,000-250,034,000746,378,000-343,210,000-295,685,000-404,819,000775,618,000-237,164,000136,731,000-38,583,00045,178,000
CFO
21m
P
-196,430,000-379,229,000-141,356,000-458,457,000-540,034,000-592,563,000-152,832,000-266,926,000-254,928,000-342,520,000-242,098,000629,069,000-21,269,0007,459,000-173,088,00020,929,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
URL
https://www.taigenbiotech.com/
IPO date
Aug 30, 2013
Employees
Domiciled in
TW
Incorporated in
KY

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT